About Poclight
Nanjing Poclight Biotechnology Co., LTD. (hereinafter referred to as "Poclight Biotechnology") is an innovative and R&D enterprise focusing on the development of in vitro medical diagnosis (IVD) platform. We have R&D and production site of 5,000 ㎡, including more than 3,700 ㎡ of GMP workshops of 10,000 level and 100,000 level.
Relying on the patent platform of "Chemiluminescence Resonance Energy Transfer (CRET)" independently developed by Poclight Biotechnology, our company has developed a number of homogeneous chemiluminescence immunoassay products, covering clinical medicine, animal medicine, drug detection and other fields, with the characteristics of "precision, accuracy, low cost, rapid, small and excellent". Adhering to the Philosophy of "innovation, convergence, concentration, win-win".
Competitive advantage
Poclight Biotechnology is fully engaged in the research and development and industrialization of “Chemiluminescence Resonance Energy Transfer” (CRET) technology. Our company has obtained the authorization of this patent, which is the only one in the world.
Our company has obvious competitive advantages in the IVD industry, which are mainly reflected in the following aspects:
1、The world's leading 5th generation chemiluminescence technology
At the technical level, the fifth generation chemiluminescence immunoassay technology is the world's exclusive, belonging to the underlying technology upgrade, and the company has complete intellectual property rights.
2、Full test items coverage with matching micro chemiluminescence
In terms of products, we achieve extremely simplified and unique product design, which not only improves product performance, but also greatly reduces costs, and improves user experience in all links, whether terminal or agent.
3、Traditional POCT technology alternative innovation
In terms of market, in the field of animal medicine to fully polish the technology and products; At the same time, the products are extremely compatible with the international market, and the foreign business supports the domestic clinical business to achieve differentiated competition. Domestic clinical business starts from the primary market, realizes the sink of chemiluminescence technology in combination with industrial policies, and then gradually occupies the secondary laboratory, tertiary emergency and bedside testing to realize the replacement of traditional POCT. Finally, it competes for the market share of tertiary laboratory under the industrial background of import substitution.
4、Global top returnee R&D team, super technology R&D strength
In terms of talents, the core team is all graduated from famous universities at home and abroad, responsible for r & D, marketing, registration, marketing, production, etc. All come from in vitro diagnosis (IVD) industry, and have an average of more than 8 years of industry experience, team implementation, strong execution, strong technical innovation.
In The Future
About animal diagnosis, we have reached cooperation with domestic agents to sell more than 2000 machines in three years. Meanwhile, international sales of pet diagnostics are well on their way.
About the IVD, clinical test products are being registered and approved, and it is expected to get 10 second-class medical device registration certificates by the end of 2021.
As a rising star of IVD, Poclight Biotechnology lays out the chemiluminescence golden track, makes use of innovative technology platform to grasp customer demand and seize the market quickly. It is estimated that the sales will reach 100 million in 2024, and sprint in 2025 to become the backbone of the fifth generation chemiluminescence technology.
